Incyte 2013 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily for oncology.

Incyte Announces Publication of Phase III RESPONSE Trial in Patients with Polycythemia Vera in New England Journal of Medicine
Incyte Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Approval in Europe for Polycythemia Vera
Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies
Jakafi® (ruxolitinib)
Connecting to Access, Reimbursement, Education and Support
To learn more, click here